Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 827 across all filing types
Latest filing 2026-05-13 Earnings Release
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance Expecting Significantly Stronger Remainder of the Year
Earnings Release Classification · 91% confidence The document is a Form 6-K filing by a foreign private issuer (Kamada Ltd.) under the Securities Exchange Act. Its principal exhibit (99.1) is a press release announcing first-quarter 2026 financial results and guidance, with key metrics (revenue, EBITDA, net income) presented as bullet points, together with conference call details. This fits the definition of an Earnings Release (ER): the initial announcement of quarterly financial results featuring highlights, rather than a full interim report with complete financial statements. Q1 2026
2026-05-13 English
Kamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance Expecting Significantly Stronger Remainder of the Year
Report Publication Announcement Classification · 92% confidence The document is an Immediate Report under ISA regulations that merely states “Attached hereto is a report on ‘Kamada Reports First Quarter 2026 Financial Results…’” and provides a PDF reference. It contains no actual financial content itself and simply announces that the report is attached. This meets the criteria for a Report Publication Announcement (RPA) rather than the report itself.
2026-05-13 English
The company's financial results for First quarter for 2026 reported abroad
Report Publication Announcement Classification · 84% confidence The document is a brief notice from the Tel Aviv Stock Exchange compliance unit stating that Kamada Ltd’s first quarter financial results “were published abroad.” It contains no actual financial statements or data, is under 5,000 characters, and simply announces the publication of a report. This aligns with a Report Publication Announcement (RPA).
2026-05-13 English
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
Regulatory Filings
2026-05-06 Hebrew (modern)
Kamada to Announce First Quarter 2026 Financial Results on May 13, 2026
Regulatory Filings
2026-05-06 Hebrew (modern)
Other Report or Announcement
Director's Dealing Classification · 94% confidence The document is an SEC Form 3 – an Initial Statement of Beneficial Ownership filed under Section 16(a) of the Securities Exchange Act, detailing personal share and option holdings by company directors/officers. This fits the insider reporting category for transactions by directors and executives. Therefore, it is a Director's Dealing filing.
2026-04-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.